Pharmacology and clinical pharmacology of methylarginines used as inhibitors of nitric oxide synthases.

Curr Pharm Des

Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Fahrstraße 17, 91054 Erlangen, Germany.

Published: March 2015

The methylarginines asymmetric dimethylarginine (ADMA) and monomethylarginine (L-NMMA) are endogenously formed inhibitors of nitric oxide synthases (NOS), which have extensively been investigated as risk markers and used as pharmacological tools to study the L-arginine-nitric oxide (NO) pathway in vitro and in vivo. It is the aim of the present review to summarize the clinical and experimental data on the pharmacological properties that are of relevance when planning and conducting experiments and clinical studies involving methylarginines. Key pharmacodynamic and pharmacokinetic data including IC50 values of ADMA and L-NMMA for NOS isoforms and transport proteins, as well as metabolism by dimethylarginine dimethylaminohydrolases (DDAH1 and DDAH2) and alanine-glyoxylate aminotransferase 2 (AGXT2) are discussed.

Download full-text PDF

Source
http://dx.doi.org/10.2174/13816128113196660750DOI Listing

Publication Analysis

Top Keywords

inhibitors nitric
8
nitric oxide
8
oxide synthases
8
pharmacology clinical
4
clinical pharmacology
4
pharmacology methylarginines
4
methylarginines inhibitors
4
synthases methylarginines
4
methylarginines asymmetric
4
asymmetric dimethylarginine
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!